Bayer Hikes 2026 Profit Outlook as Pharma Unit Beats Expectations
The German group lifted adjusted core earnings guidance to €9.8 billion to €10.3 billion after pharmaceuticals sales topped expectations by 5%, according to Vara Research.
- On Tuesday, German pharmaceuticals and agriculture group Bayer raised its 2026 profit outlook, citing better-than-anticipated performance in its pharmaceuticals business. Stock rose 2% in early Frankfurt trade.
- Chief Executive Bill Anderson stated, "We've reached a turning point in Pharma's growth trajectory and we're beginning to see the other side." The company achieved adjusted core earnings of €1.62 billion, around 13% ahead of analyst expectations.
- Bayer's pharmaceuticals division posted sales of €4.68 billion in the third quarter, 5% above analyst expectations. The crop science division achieved adjusted core earnings of €101 million, missing the €164 million target amid weak sales in EMEA and Asia Pacific.
- Management cut net financial debt expectations for the year by €1 billion, now projecting between €28 billion and €29 billion. Adjusted core earnings forecast was raised to between €9.8 billion and €10.3 billion.
- Long-Term financial pressure persists for the group, which remains weighed down by heavy debt since its $63 billion acquisition of Monsanto in 2018. This deal also burdened Bayer with costly Roundup litigation affecting its financial profile.
17 Articles
17 Articles
Bayer raised its profit projections for the year, driven by the strong recovery of its pharmaceutical division, whose demand for new medicines compensated for the market pressures faced in the agricultural and consumer health units. Exclusive material for subscribers. To have full access, access the link of the subject and register.
The Leverkusen group (west) now aims in a press release an adjusted operating profit (Ebitda) before exceptional items from 9,8 to 10,3 billion euros, a range of 200 million euros higher than before. The margin of Ebitda before exceptional elements of the pharmaceutical division was also raised by two points, expected between 25 and 27%. "We have now reached a tipping point in the growth trajectory of +Pharmaceuticals+ (prescription medicines), …
Bayer hikes 2026 profit outlook as pharma unit beats expectations - Regional Media News
By Tristan Veyet and Patricia Weiss Nov 3 (Reuters) - German pharmaceuticals and agriculture group Bayer on Tuesday raised its 2026 profit outlook, citing a better-than-anticipated performance at the company's pharmaceuticals business. Bayer's stock was up 2% in early Frankfurt trade. Bayer has been weighed [...]
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D24&w=64&q=75){kind=small}
Bayer Raises 2026 Profit Forecast After Pharmaceutical Business Exceeds Expectations
Bayer has raised its 2026 earnings outlook after stronger-than-expected pharmaceutical sales helped compensate for weaker results in its agricultural division. The company also lowered its ... The post Bayer Raises 2026 Profit Forecast After Pharmaceutical Business Exceeds Expectations first appeared on [your]NEWS.
Bayer raises 2026 profit outlook on strong pharmaceuticals performance
Bayer raised its 2026 profit outlook after its pharmaceuticals division delivered stronger-than-expected third-quarter sales. The German group also lowered its debt forecast, signalling improving growth momentum and a stronger financial position.
Bayer hikes 2026 profit outlook as pharma unit beats expectations
By Tristan Veyet and Patricia Weiss Nov 3 (Reuters) - German pharmaceuticals and agriculture group Bayer on Tuesday raised its 2026 profit outlook, citing a better-than-anticipated performance at the company's pharmaceuticals business. Bayer's stock ...
Coverage Details
Bias Distribution
- 62% of the sources lean Right
![[your]NEWS](/_next/image?url=https%3A%2F%2Fgroundnews.b-cdn.net%2Finterests%2Ffb6dc495f74049f513563c33352175eaa0ecd509.jpg%3Fwidth%3D60&w=128&q=75)
Factuality
To view factuality data please Upgrade to Premium
